Text Size

Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00526552
First received: September 5, 2007
Last updated: March 29, 2010
Last verified: March 2010
History of Changes
  Purpose

To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes


Condition
Dyslipidemia
Diabetes

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: RAPID (Evaluating the Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes in Real World Practice)

Resource links provided by NLM:

MedlinePlus related topics: Diabetes
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Estimated Enrollment: 5000
Study Start Date: June 2007
Study Completion Date: December 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Diabetic Mellitus patients with hypercholesteromia in Korean tertiary care centers

Criteria

Inclusion Criteria:

  • Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria

    1. Over 18 years of age
    2. Diagnosed with DM based on fasting or post-load glucose data and/or clinical assessment by the clinician

Exclusion Criteria:

  1. Patients already taking other hyperlipidemic agents
  2. Patients who do not fulfil the indication criteria for statin therapy
  3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00526552

Locations
Korea, Republic of
Research Site
Seoul, Jongro-gu, Korea, Republic of
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Research Site
Seoul, Songpa-gu, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Hyunah Caroline Choi AstraZeneca Korea
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00526552     History of Changes
Other Study ID Numbers: NIS-CKR-CRE-2007/3
Study First Received: September 5, 2007
Last Updated: March 29, 2010
Health Authority: Korea: Food and Drug Administration

Keywords provided by AstraZeneca:
dyslipidemia
rosuvastatin
diabetes
 cholesterol
Naturalistic
Observational

Additional relevant MeSH terms:
Diabetes Mellitus
Dyslipidemias
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Lipid Metabolism Disorders
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
 Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013